
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Salvage therapy containing sorafenib and donor lymphocyte infusion is associated with improved outcomes for FLT3 wild-type acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="AE532F8F8AF23053052F8F0059389945.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="biomarkerres">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366021/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Biomarker Research">
<meta name="citation_title" content="Salvage therapy containing sorafenib and donor lymphocyte infusion is associated with improved outcomes for FLT3 wild-type acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation">
<meta name="citation_author" content="Zhonghui Jiang">
<meta name="citation_author_institution" content="Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China">
<meta name="citation_author_institution" content="Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China">
<meta name="citation_author" content="Ya Zhou">
<meta name="citation_author_institution" content="Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China">
<meta name="citation_author_institution" content="Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China">
<meta name="citation_author" content="Yuxin Bai">
<meta name="citation_author_institution" content="Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China">
<meta name="citation_author_institution" content="Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China">
<meta name="citation_author" content="Fang Dai">
<meta name="citation_author_institution" content="Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China">
<meta name="citation_author_institution" content="Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China">
<meta name="citation_author" content="Menglin Fan">
<meta name="citation_author_institution" content="Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China">
<meta name="citation_author_institution" content="Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China">
<meta name="citation_author" content="Tian Zhang">
<meta name="citation_author_institution" content="Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China">
<meta name="citation_author_institution" content="Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China">
<meta name="citation_author" content="Danian Nie">
<meta name="citation_author_institution" content="Department of Hematology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China">
<meta name="citation_author" content="Yunxin Zeng">
<meta name="citation_author_institution" content="Department of Hematology, Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China">
<meta name="citation_author" content="Yirong Jiang">
<meta name="citation_author_institution" content="Department of Hematology, Dongguan People’s Hospital, Southern Medical University, Dongguan, China">
<meta name="citation_author" content="Ping Zhu">
<meta name="citation_author_institution" content="Department of Hematology, First People’s Hospital of Chenzhou, Chenzhou, China">
<meta name="citation_author" content="Zhiping Fan">
<meta name="citation_author_institution" content="Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China">
<meta name="citation_author_institution" content="Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China">
<meta name="citation_author" content="Na Xu">
<meta name="citation_author_institution" content="Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China">
<meta name="citation_author_institution" content="Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China">
<meta name="citation_author" content="Fen Huang">
<meta name="citation_author_institution" content="Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China">
<meta name="citation_author_institution" content="Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China">
<meta name="citation_author" content="Ren Lin">
<meta name="citation_author_institution" content="Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China">
<meta name="citation_author_institution" content="Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China">
<meta name="citation_author" content="Min Dai">
<meta name="citation_author_institution" content="Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China">
<meta name="citation_author_institution" content="Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China">
<meta name="citation_author" content="Xiaojun Xu">
<meta name="citation_author_institution" content="Department of Hematology, Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China">
<meta name="citation_author" content="Zhangkun Li">
<meta name="citation_author_institution" content="Department of Hematology, Dongguan People’s Hospital, Southern Medical University, Dongguan, China">
<meta name="citation_author" content="Hua Jin">
<meta name="citation_author_institution" content="Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China">
<meta name="citation_author_institution" content="Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China">
<meta name="citation_author" content="Jing Sun">
<meta name="citation_author_institution" content="Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China">
<meta name="citation_author_institution" content="Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China">
<meta name="citation_author" content="Qifa Liu">
<meta name="citation_author_institution" content="Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China">
<meta name="citation_author_institution" content="Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China">
<meta name="citation_author" content="Li Xuan">
<meta name="citation_author_institution" content="Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China">
<meta name="citation_author_institution" content="Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China">
<meta name="citation_publication_date" content="2025 Aug 20">
<meta name="citation_volume" content="13">
<meta name="citation_firstpage" content="106">
<meta name="citation_doi" content="10.1186/s40364-025-00816-9">
<meta name="citation_pmid" content="40830801">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366021/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366021/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366021/pdf/40364_2025_Article_816.pdf">
<meta name="description" content="There is no established standard treatment for acute myeloid leukemia (AML) patients with FLT3 wild-type relapsing after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Multi-kinase inhibitor sorafenib has been widely explored in the ...">
<meta name="og:title" content="Salvage therapy containing sorafenib and donor lymphocyte infusion is associated with improved outcomes for FLT3 wild-type acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="There is no established standard treatment for acute myeloid leukemia (AML) patients with FLT3 wild-type relapsing after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Multi-kinase inhibitor sorafenib has been widely explored in the ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366021/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12366021">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s40364-025-00816-9"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/40364_2025_Article_816.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12366021%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12366021/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12366021/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366021/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-biomarkerres.png" alt="Biomarker Research logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Biomarker Research" title="Link to Biomarker Research" shape="default" href="https://biomarkerres.biomedcentral.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Biomark Res</button></div>. 2025 Aug 20;13:106. doi: <a href="https://doi.org/10.1186/s40364-025-00816-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s40364-025-00816-9</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Biomark%20Res%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Biomark%20Res%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Biomark%20Res%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Biomark%20Res%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Salvage therapy containing sorafenib and donor lymphocyte infusion is associated with improved outcomes for FLT3 wild-type acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jiang%20Z%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Zhonghui Jiang</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Zhonghui Jiang</span></h3>
<div class="p">
<sup>1</sup>Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China </div>
<div class="p">
<sup>2</sup>Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jiang%20Z%22%5BAuthor%5D" class="usa-link"><span class="name western">Zhonghui Jiang</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhou%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Ya Zhou</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Ya Zhou</span></h3>
<div class="p">
<sup>1</sup>Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China </div>
<div class="p">
<sup>2</sup>Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhou%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Ya Zhou</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bai%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Yuxin Bai</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Yuxin Bai</span></h3>
<div class="p">
<sup>1</sup>Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China </div>
<div class="p">
<sup>2</sup>Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bai%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yuxin Bai</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dai%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Fang Dai</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Fang Dai</span></h3>
<div class="p">
<sup>1</sup>Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China </div>
<div class="p">
<sup>2</sup>Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dai%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Fang Dai</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fan%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Menglin Fan</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Menglin Fan</span></h3>
<div class="p">
<sup>1</sup>Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China </div>
<div class="p">
<sup>2</sup>Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fan%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Menglin Fan</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Tian Zhang</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Tian Zhang</span></h3>
<div class="p">
<sup>1</sup>Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China </div>
<div class="p">
<sup>2</sup>Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Tian Zhang</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nie%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Danian Nie</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Danian Nie</span></h3>
<div class="p">
<sup>3</sup>Department of Hematology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nie%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Danian Nie</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zeng%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Yunxin Zeng</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Yunxin Zeng</span></h3>
<div class="p">
<sup>4</sup>Department of Hematology, Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zeng%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yunxin Zeng</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jiang%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Yirong Jiang</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Yirong Jiang</span></h3>
<div class="p">
<sup>5</sup>Department of Hematology, Dongguan People’s Hospital, Southern Medical University, Dongguan, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jiang%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yirong Jiang</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhu%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Ping Zhu</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Ping Zhu</span></h3>
<div class="p">
<sup>6</sup>Department of Hematology, First People’s Hospital of Chenzhou, Chenzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhu%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Ping Zhu</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fan%20Z%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Zhiping Fan</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Zhiping Fan</span></h3>
<div class="p">
<sup>1</sup>Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China </div>
<div class="p">
<sup>2</sup>Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fan%20Z%22%5BAuthor%5D" class="usa-link"><span class="name western">Zhiping Fan</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Na Xu</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Na Xu</span></h3>
<div class="p">
<sup>1</sup>Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China </div>
<div class="p">
<sup>2</sup>Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Na Xu</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Fen Huang</span></a><div hidden="hidden" id="id13">
<h3><span class="name western">Fen Huang</span></h3>
<div class="p">
<sup>1</sup>Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China </div>
<div class="p">
<sup>2</sup>Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Fen Huang</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lin%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Ren Lin</span></a><div hidden="hidden" id="id14">
<h3><span class="name western">Ren Lin</span></h3>
<div class="p">
<sup>1</sup>Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China </div>
<div class="p">
<sup>2</sup>Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lin%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Ren Lin</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dai%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Min Dai</span></a><div hidden="hidden" id="id15">
<h3><span class="name western">Min Dai</span></h3>
<div class="p">
<sup>1</sup>Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China </div>
<div class="p">
<sup>2</sup>Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dai%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Min Dai</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Xiaojun Xu</span></a><div hidden="hidden" id="id16">
<h3><span class="name western">Xiaojun Xu</span></h3>
<div class="p">
<sup>4</sup>Department of Hematology, Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xiaojun Xu</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20Z%22%5BAuthor%5D" class="usa-link" aria-describedby="id17"><span class="name western">Zhangkun Li</span></a><div hidden="hidden" id="id17">
<h3><span class="name western">Zhangkun Li</span></h3>
<div class="p">
<sup>5</sup>Department of Hematology, Dongguan People’s Hospital, Southern Medical University, Dongguan, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20Z%22%5BAuthor%5D" class="usa-link"><span class="name western">Zhangkun Li</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jin%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id18"><span class="name western">Hua Jin</span></a><div hidden="hidden" id="id18">
<h3><span class="name western">Hua Jin</span></h3>
<div class="p">
<sup>1</sup>Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China </div>
<div class="p">
<sup>2</sup>Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jin%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hua Jin</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sun%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id19"><span class="name western">Jing Sun</span></a><div hidden="hidden" id="id19">
<h3><span class="name western">Jing Sun</span></h3>
<div class="p">
<sup>1</sup>Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China </div>
<div class="p">
<sup>2</sup>Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sun%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jing Sun</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20Q%22%5BAuthor%5D" class="usa-link" aria-describedby="id20"><span class="name western">Qifa Liu</span></a><div hidden="hidden" id="id20">
<h3><span class="name western">Qifa Liu</span></h3>
<div class="p">
<sup>1</sup>Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China </div>
<div class="p">
<sup>2</sup>Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20Q%22%5BAuthor%5D" class="usa-link"><span class="name western">Qifa Liu</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xuan%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id21"><span class="name western">Li Xuan</span></a><div hidden="hidden" id="id21">
<h3><span class="name western">Li Xuan</span></h3>
<div class="p">
<sup>1</sup>Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China </div>
<div class="p">
<sup>2</sup>Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xuan%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Li Xuan</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China </div>
<div id="Aff2">
<sup>2</sup>Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China </div>
<div id="Aff3">
<sup>3</sup>Department of Hematology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China </div>
<div id="Aff4">
<sup>4</sup>Department of Hematology, Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China </div>
<div id="Aff5">
<sup>5</sup>Department of Hematology, Dongguan People’s Hospital, Southern Medical University, Dongguan, China </div>
<div id="Aff6">
<sup>6</sup>Department of Hematology, First People’s Hospital of Chenzhou, Chenzhou, China </div>
<div class="author-notes p">
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
<div class="fn" id="_eqcntrb93pmc__">
<sup>#</sup><p class="display-inline">Contributed equally.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Jun 24; Accepted 2025 Aug 1; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a>. The Creative Commons Public Domain Dedication waiver (<a href="https://creativecommons.org/publicdomain/zero/1.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/publicdomain/zero/1.0/</a>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12366021  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40830801/" class="usa-link">40830801</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background</h3>
<p id="Par1">There is no established standard treatment for acute myeloid leukemia (AML) patients with FLT3 wild-type relapsing after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Multi-kinase inhibitor sorafenib has been widely explored in the treatment of AML patients with FLT3 internal tandem duplication (FLT3-ITD) mutations. Some studies have revealed that the addition of sorafenib to standard chemotherapy could improve outcomes in newly diagnosed AML regardless of FLT3 status. However, the application of sorafenib in FLT3 wild-type AML patients experiencing relapse after allo-HSCT remains minimally investigated.</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods</h3>
<p id="Par2">We retrospectively compared the effects of conventional treatment combined with or without sorafenib on the outcomes of these patients. The study mainly focused on the treatment response of salvage therapy and survival.</p></section><section id="sec3"><h3 class="pmc_sec_title">Results</h3>
<p id="Par3">Sixty-two AML patients with FLT3 wild-type who relapsed after allo-HSCT were enrolled in this study, including 38 with sorafenib and 24 without sorafenib. Fifty patients received 68 doses of donor lymphocyte infusion (DLI). The rate of composite complete remission was 65.8% in the sorafenib group, compared with 29.2% in the non-sorafenib group (<em>P</em> = 0.005). With a median follow-up of 13.2 months (IQR, 3.2–43.5) after relapse, the 2-year overall survival (OS) was 47.4% (95%CI, 33.9%-66.2%) and 16.7% (6.8%-40.8%) in the sorafenib and non-sorafenib groups (<em>P</em> = 0.006). The 2-year event-free survival (EFS) was 44.7% (31.4%-63.7%) and 16.7% (6.8%-40.8%) in the two groups (<em>P</em> = 0.012). Multivariable analysis revealed that salvage therapy including sorafenib was the protective factor for longer OS and EFS (HR = 0.395, 95% CI: 0.209–0.746, <em>P</em> = 0.004; HR = 0.406, 95% CI: 0.218–0.754, <em>P</em> = 0.004). The incidences of acute graft-versus-host disease (GVHD) and chronic GVHD were similar between the two groups (<em>P</em> = 0.806, <em>P</em> = 0.908).</p></section><section id="sec4"><h3 class="pmc_sec_title">Conclusion</h3>
<p id="Par4">Our results suggest that salvage therapy including sorafenib and DLI is associated with improved outcomes for AML patients with FLT3 wild-type relapsing after allo-HSCT.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Sorafenib, Relapse after allogeneic hematopoietic stem cell transplantation, Salvage therapy, FLT3 wide-type</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Background</h2>
<p id="Par5">Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for acute myeloid leukemia (AML). However, post-transplant relapse occurs in a considerable proportion of patients. Patients who experience leukemia relapse post-transplantation have a poor prognosis, with the 2-year overall survival (OS) of only 20% [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>–<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>]. To date, there is no established standard treatment for post-transplant relapse. Conventional therapeutic options include chemotherapy, donor lymphocyte infusion (DLI), and second allo-HSCT. Despite such treatments, however, the efficacy is limited [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>–<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>].</p>
<p id="Par6">Currently, the multi-kinase inhibitor sorafenib has been widely explored in the treatment of AML [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>–<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>]. Sorafenib maintenance post-transplantation has been recommended as first-line treatment in AML patients with FLT3 internal tandem duplication (FLT3-ITD) mutations by multiple guidelines [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>, <a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]. Several studies have revealed that the addition of sorafenib to standard chemotherapy could result in improved survival in newly-diagnosed AML, irrespective of the FLT3-mutation status [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>, <a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>, <a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>]. However, there are few studies on the use of sorafenib in AML patients with FLT3 wild-type who relapse after allo-HSCT. Our previous study has demonstrated that sorafenib combined with chemotherapy and DLI is also effective for patients with FLT3 wild-type AML relapsing after allo-HSCT [<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>]. Apart from targeting multiple kinases, growing evidence has shown that the antitumor effect of sorafenib is related to immunomodulatory activity [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>, <a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>]. Considering the enhancement effect of sorafenib on graft-versus-leukemia (GVL), we conducted a retrospective exploratory study to compare conventional therapeutic strategies combined with or without sorafenib for AML patients with FLT3 wild-type who relapsed after allo-HSCT.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Methods</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Patients and data collection</h3>
<p id="Par7">This retrospective study examined all consecutive AML patients with FLT3 wild-type who experienced hematologic and/or extramedullary relapse after allo-HSCT at 5 hospitals (Nanfang Hospital, Sun Yat-sen Memorial Hospital, Seventh Affiliated Hospital of Sun Yat-sen University, Dongguan People’s Hospital and First People’s Hospital of Chenzhou) from November 2017 to December 2022. In our five centers, molecular biology including FLT3 mutation status was evaluated at the initial diagnosis. Most patients did molecular genetics analysis including FLT3 mutation status at relapse both pre-transplant and post-transplant. Patients were eligible for this study if they were FLT3 wild-type at the initial diagnosis and at relapse after allo-HSCT. Patients were excluded from the study if they gave up further treatment after relapse post-transplant.</p>
<p id="Par8">Data were obtained from patients’ medical records. Variables collected for all patients included demographic information, pre-transplant-related parameters, transplant-related parameters, post-transplant-related parameters, relapse-related parameters post-transplant, treatment-related parameters, and survival. The trial was first approved by Medical Ethics Committee of Nanfang Hospital of Southern Medical University. Subsequently, the remaining four centers conducted ethical filing. This trial was reviewed and approved by the ethics committee review board at each participating center and was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all the patients.</p></section><section id="Sec4"><h3 class="pmc_sec_title">Measurable residual disease (MRD) detection</h3>
<p id="Par9">Generally, bone marrow (BM) was evaluated at 1, 2, 3, 4, 6, 8, 10, and 12 months within 1-year post-transplantation, then at 3-month intervals during second year, 4-month intervals within third year, and half-year intervals from fourth to fifth year. MRD was evaluated by eight-color multi-parameter flow cytometry (MFC) with a threshold of 0.01%. MRD was also monitored by quantitative polymerase chain reaction (PCR) for leukemia-related specific genes including RUNX1-RUNX1T1and CBFβ/MYH11, with a threshold of 0.001%. Patients were defined as MRD positivity if they had two consecutive positive results using MFC or PCR or were both positive in a single sample. Preemptive therapy was conducted in patients with MRD positive post-transplant.</p></section><section id="Sec5"><h3 class="pmc_sec_title">Evaluation points and definitions</h3>
<p id="Par10">This study mainly focused on the treatment response of salvage therapy and survival. Leukemia relapse was defined as either reappearance of leukemic blasts in the peripheral blood or at least 5% blasts in the BM aspirate or biopsy specimen not attributable to any other cause, or reappearance or new appearance of extramedullary leukemia. Response criteria were defined according to the European Leukemia Net (ELN) 2022 guidelines [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. Complete remission (CR) was defined as BM blasts less than 5%, absence of circulating blasts and absence of extramedullary disease, and an absolute neutrophil count of 1.0 × 10⁹ cells/L or higher and a platelet count of 100 × 10⁹/L or higher. Complete remission with incomplete hematological recovery (CRi) met all criteria for CR except that for residual neutropenia (absolute neutrophil count &lt; 1.0 × 10⁹ cells/L), thrombocytopenia (platelets &lt; 100 × 10⁹ cells/L) or both. Composite complete remission (CRc) comprised CR and CRi. Non-remission (NR) was defined as a failure to obtain CRc.</p>
<p id="Par11">OS was defined as the time from the initiation of salvage therapy until death or last follow-up. Event-free survival (EFS) was defined as the time from salvage therapy until documented failure to achieve CRc, relapse after CRc, or death from any cause, whichever occurred first. Acute graft-versus-host disease (aGVHD) was graded according to the 1994 Consensus Conference on Acute GVHD Grading [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>], and chronic GVHD (cGVHD) was graded according to the National Institutes of Health criteria [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>]. The timing of GVHD before relapse was defined as the interval from HSCT to the onset of GVHD. The timing of GVHD after relapse was defined as the interval from the start of salvage therapy to the onset of GVHD.</p></section><section id="Sec6"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p id="Par12">The study data were analyzed on December 31, 2024. The descriptive analysis of patient characteristics included median and interquartile range (IQR) for continuous variables, and absolute and relative frequencies for categorical variables. The χ² test was used to assess categorical variables and the Mann-Whitney U test was used for continuous variables. The CRc rate and two-sided 95% confidence intervals (CIs) were calculated with the Wilson method. OS and EFS were analyzed by the Kaplan-Meier method and compared using the log-rank test. The corresponding hazard ratio (HR) and 95% CI were estimated using the Cox proportional hazards model. Cumulative incidence of GVHD was calculated by accounting for competing risk. Death due to other causes was considered a competing event for GVHD. The comparison of the cumulative incidence in the presence of a competing risk was done using the Fine and Gray model [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]. The Cox proportional hazards model was used for the analysis of risk factors for time-to-event variables. The test indicated that the proportional hazards assumptions held. Variables included in the univariable analysis were gender, age, disease status at transplant, donor type, ELN classification, relapse type post-transplant, relapse time post-transplant, salvage therapy including sorafenib, salvage therapy including DLI, and acute and chronic GVHD after salvage therapy. Only variables with a p value less than 0.10 were included in the multivariable analysis. All statistical tests were two-tailed with a significance level of 0.05. SPSS version 25.0 and R version 3.3.0 were used for data analysis.</p></section></section><section id="Sec7"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec8"><h3 class="pmc_sec_title">Patient characteristics</h3>
<p id="Par13">Except for the 14 patients who abandoned further treatment after relapse, 62 AML patients with FLT3 wild-type who relapsed after allo-HSCT were enrolled in this study. The median age at the time of transplant was 35.5 years old (IQR, 29 to 48.5), and there were 42 male and 20 female. With respect to ELN 2022 risk, 4 (6.5%), 14 (22.6%), and 44 (71.0%) patients were favorable-, intermediate-, and adverse-risk, respectively. Forty patients were in first complete remission, 5 in ≥ second complete remission, and 17 in NR at the time of transplant. Thirty-two patients received HLA-matched sibling donor and 30 received HLA-haploidentical related donor transplant. The 62 patients all achieved CRc and complete chimerism by day + 30 post-transplant.</p>
<p id="Par14">With a median time of 192.5 days (IQR, 94.0-397.5) after allo-HSCT, 47 patients experienced hematologic relapse, 7 extramedullary relapse, and 8 hematologic accompanied by extramedullary relapse. Based on sorafenib inclusion in salvage therapy, patients were divided into two groups: sorafenib (<em>n</em> = 38) and non-sorafenib (<em>n</em> = 24). The baseline factors of patients’ characteristics were well balanced between the two groups (Table <a href="#Tab1" class="usa-link">1</a>). None of the patients received any FLT3 inhibitors other than sorafenib for salvage treatment. There was also no history of sorafenib use prior to relapse after transplantation.</p>
<section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Patients’ clinical and transplant characteristics</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1">Entire sample<br>(<em>n</em> = 62)</th>
<th align="left" colspan="1" rowspan="1">Sorafenib Group (<em>n</em> = 38)</th>
<th align="left" colspan="1" rowspan="1">Non-sorafenib Group (<em>n</em> = 24)</th>
<th align="left" colspan="1" rowspan="1">
<em>P</em>
</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Median age at transplant, yr (IQR)</td>
<td align="left" colspan="1" rowspan="1">35.5(29-48.5)</td>
<td align="left" colspan="1" rowspan="1">33(28.6–47.8)</td>
<td align="left" colspan="1" rowspan="1">37(32.3–51)</td>
<td align="left" colspan="1" rowspan="1">0.424</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Gender</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.331</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Male</td>
<td align="left" colspan="1" rowspan="1">42(67.7%)</td>
<td align="left" colspan="1" rowspan="1">24(63.2%)</td>
<td align="left" colspan="1" rowspan="1">18(75.0%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Female</td>
<td align="left" colspan="1" rowspan="1">20(32.3%)</td>
<td align="left" colspan="1" rowspan="1">14(36.8%)</td>
<td align="left" colspan="1" rowspan="1">6(25.0%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ELN classification<sup>#</sup>, No (%)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.811</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Favorable</td>
<td align="left" colspan="1" rowspan="1">4(6.5%)</td>
<td align="left" colspan="1" rowspan="1">2(5.3%)</td>
<td align="left" colspan="1" rowspan="1">2(8.3%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Intermediate</td>
<td align="left" colspan="1" rowspan="1">14(22.6%)</td>
<td align="left" colspan="1" rowspan="1">8(21.1%)</td>
<td align="left" colspan="1" rowspan="1">6(25.0%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Adverse</td>
<td align="left" colspan="1" rowspan="1">44 (71.0%)</td>
<td align="left" colspan="1" rowspan="1">28(73.7%)</td>
<td align="left" colspan="1" rowspan="1">16(66.7%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Disease status at transplant</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.692</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> CR1</td>
<td align="left" colspan="1" rowspan="1">40(64.5%)</td>
<td align="left" colspan="1" rowspan="1">26(68.4%)</td>
<td align="left" colspan="1" rowspan="1">14(58.3%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> ≥CR2</td>
<td align="left" colspan="1" rowspan="1">5(8.1%)</td>
<td align="left" colspan="1" rowspan="1">3(7.9%)</td>
<td align="left" colspan="1" rowspan="1">2(8.3%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> NR</td>
<td align="left" colspan="1" rowspan="1">17(27.4%)</td>
<td align="left" colspan="1" rowspan="1">9(23.7%)</td>
<td align="left" colspan="1" rowspan="1">8(33.4%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Donor type</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.213</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> HLA-matched sibling</td>
<td align="left" colspan="1" rowspan="1">32(51.6%)</td>
<td align="left" colspan="1" rowspan="1">22(57.9%)</td>
<td align="left" colspan="1" rowspan="1">10(41.7%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> HLA-haploidentical related</td>
<td align="left" colspan="1" rowspan="1">30(48.4%)</td>
<td align="left" colspan="1" rowspan="1">16(42.1%)</td>
<td align="left" colspan="1" rowspan="1">14(58.3%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Median relapse time post-transplant, days (IQR)</td>
<td align="left" colspan="1" rowspan="1">
<p>192.5</p>
<p>(94-397.5)</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>192.5</p>
<p>(92.3–476.0)</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>194.5</p>
<p>(104.3–314.0)</p>
</td>
<td align="left" colspan="1" rowspan="1">0.426</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">aGVHD before relapse</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.715</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No aGVHD</td>
<td align="left" colspan="1" rowspan="1">43(69.4%)</td>
<td align="left" colspan="1" rowspan="1">27(71.1%)</td>
<td align="left" colspan="1" rowspan="1">16(66.7%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> aGVHD</td>
<td align="left" colspan="1" rowspan="1">19(30.6%)</td>
<td align="left" colspan="1" rowspan="1">11(28.9%)</td>
<td align="left" colspan="1" rowspan="1">8(33.3%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">cGVHD before relapse</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.984</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No cGVHD</td>
<td align="left" colspan="1" rowspan="1">49(79.0%)</td>
<td align="left" colspan="1" rowspan="1">30(78.9%)</td>
<td align="left" colspan="1" rowspan="1">19(79.2%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> cGVHD</td>
<td align="left" colspan="1" rowspan="1">13(21.0%)</td>
<td align="left" colspan="1" rowspan="1">8(21.1%)</td>
<td align="left" colspan="1" rowspan="1">5(20.8%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Relapse type post-transplant</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.971</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Hematologic</td>
<td align="left" colspan="1" rowspan="1">47(75.8%)</td>
<td align="left" colspan="1" rowspan="1">29(76.3%)</td>
<td align="left" colspan="1" rowspan="1">18(75.0%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Extramedullary</td>
<td align="left" colspan="1" rowspan="1">7(11.3%)</td>
<td align="left" colspan="1" rowspan="1">4(10.5%)</td>
<td align="left" colspan="1" rowspan="1">3(12.5%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Hematologic + extramedullary</td>
<td align="left" colspan="1" rowspan="1">8(12.9%)</td>
<td align="left" colspan="1" rowspan="1">5(13.2%)</td>
<td align="left" colspan="1" rowspan="1">3(12.5%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p23"><p>Data are n (%) or median (IQR). Percentages might not total 100 because of rounding. ELN, European Leukemia Net; CR1, first complete remission; CR2, second complete remission; NR, no response; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease. <sup>#</sup>referred to 2022 European Leukemia Net risk stratification</p></div></div></section></section><section id="Sec9"><h3 class="pmc_sec_title">Salvage therapies and response</h3>
<p id="Par17">Once patients relapsed after allo-HSCT, immunosuppressants were withdrawn/ stopped immediately, and salvage therapy was taken. Four salvage regimens were administered after relapse post-transplant, including sorafenib combined with chemotherapy followed by DLI (<em>n</em> = 33), sorafenib combined with chemotherapy (<em>n</em> = 5), chemotherapy followed by DLI (<em>n</em> = 17) and monochemotherapy (<em>n</em> = 7). Besides, 5 patients with extramedullary relapse also received radiotherapy.</p>
<p id="Par18">Thirty-eight patients were treated with sorafenib for a median duration of 360 days (IQR, 121 to 522) after relapse post-transplant. Sorafenib was usually used at the beginning of induction chemotherapy. The initial dose of sorafenib was 400 mg twice daily and adjusted based on suspected toxicity (dose range, 200 to 800 mg daily). The chemotherapy regimens included venetoclax, homoharringtonine and azacytidine (VAH) regimen (<em>n</em> = 30), venetoclax and azacytidine (VA) regimen (<em>n</em> = 6), decitabine, aclacinomycin, cytarabine and granulocyte colony-stimulating factor (DAC-CAG) regimen (<em>n</em> = 15) and other regimens (<em>n</em> = 11). For patients without grades II to &gt; II aGVHD or extensive cGVHD at the time of relapse, granulocyte colony-stimulating factor (G-CSF)-mobilized DLI was administered at the following day of chemotherapy end if donor lymphocytes were available. Eighty-eight DLI doses were administered to 50 patients, with a median of once per patient (IQR, 1 to 2) and a median dosage of 3.0 × 10<sup>7</sup> CD3<sup>+</sup> T cells/kg (IQR, 2.5 to 4.3).</p>
<p id="Par19">Thirty-eight patients in the sorafenib group received chemotherapy regimens including VAH regimen (<em>n</em> = 22), VA regimen (<em>n</em> = 4), DAC-CAG regimen (<em>n</em> = 7) and other regimens (<em>n</em> = 5). Twenty-four patients in the non-sorafenib group received chemotherapy regimens including VAH regimen (<em>n</em> = 8), VA regimen (<em>n</em> = 2), DAC-CAG regimen (<em>n</em> = 8) and other regimens (<em>n</em> = 6). In the sorafenib group, 54 doses of DLI were administered in 33 of 38 patients, with a median of once per patient (IQR, 1 to 2). In the non-sorafenib group, thirty-four doses of DLI were administered to 17 of 24 patients, with a median of once per patient (IQR, 1 to 3).</p>
<p id="Par20">Thirty-two patients achieved CRc after salvage therapy, with the CRc rate of 51.6% (32 of 62 patients; 95% CI, 39.5%-63.6%). The CRc rate was 65.8% (25 of 38 patients; 95% CI, 49.9%-78.8%) in the sorafenib group, compared with 29.2% (7 of 24 patients; 95% CI, 14.9%-49.2%) in the non-sorafenib group (<em>P</em> = 0.005, Fig. <a href="#Fig1" class="usa-link">1</a>, Table <a href="#Tab2" class="usa-link">2</a>).</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366021_40364_2025_816_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e708/12366021/25dff1d8a502/40364_2025_816_Fig1_HTML.jpg" loading="lazy" id="d33e962" height="325" width="669" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>The response of patients who relapsed post-transplant receiving salvage therapy with or without sorafenib. CRc, composite complete remission; NR, no response</p></figcaption></figure><section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Outcomes after salvage therapy</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1">Entire sample<br>(<em>n</em> = 62)</th>
<th align="left" colspan="1" rowspan="1">Sorafenib Group (<em>n</em> = 38)</th>
<th align="left" colspan="1" rowspan="1">Non-sorafenib Group (<em>n</em> = 24)</th>
<th align="left" colspan="1" rowspan="1">
<em>P</em>
</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">CRc rate, No. (% [95% CI])</td>
<td align="left" colspan="1" rowspan="1">
<p>32 (51.6</p>
<p>[39.5–63.6])</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>25(65.8</p>
<p>[49.9–78.8])</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>7(29.2</p>
<p>[14.9–49.2])</p>
</td>
<td align="left" colspan="1" rowspan="1">*0.005</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">OS</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Median, months (95% CI)</td>
<td align="left" colspan="1" rowspan="1">12.8(3.2–22.5)</td>
<td align="left" colspan="1" rowspan="1">18.4(0-50.8)</td>
<td align="left" colspan="1" rowspan="1">4.8(2.0-7.6)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> 1-year OS, % (95% CI)</td>
<td align="left" colspan="1" rowspan="1">51.6(40.6–65.7)</td>
<td align="left" colspan="1" rowspan="1">63.2(49.5–80.5)</td>
<td align="left" colspan="1" rowspan="1">33.3(18.9–58.7)</td>
<td align="left" colspan="1" rowspan="1">*0.016</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Estimated 2-year OS, % (95% CI)</td>
<td align="left" colspan="1" rowspan="1">35.5(25.4–49.6)</td>
<td align="left" colspan="1" rowspan="1">47.4(33.9–66.2)</td>
<td align="left" colspan="1" rowspan="1">16.7(6.8–40.8)</td>
<td align="left" colspan="1" rowspan="1">*0.006</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">EFS</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Median, months (95% CI)</td>
<td align="left" colspan="1" rowspan="1">4.3(0-11.4)</td>
<td align="left" colspan="1" rowspan="1">11.4(0-32.2)</td>
<td align="left" colspan="1" rowspan="1">2.3(0.2–4.3)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> 1-year EFS, % (95% CI)</td>
<td align="left" colspan="1" rowspan="1">40.3(29.8–54.6)</td>
<td align="left" colspan="1" rowspan="1">50.0(36.4–68.7)</td>
<td align="left" colspan="1" rowspan="1">25.0(12.5–50.0)</td>
<td align="left" colspan="1" rowspan="1">*0.037</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Estimated 2-year EFS, % (95% CI)</td>
<td align="left" colspan="1" rowspan="1">33.9(23.9–48.0)</td>
<td align="left" colspan="1" rowspan="1">44.7(31.4–63.7)</td>
<td align="left" colspan="1" rowspan="1">16.7(6.8–40.8)</td>
<td align="left" colspan="1" rowspan="1">*0.012</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p36"><p>Abbreviations: CRc, composite complete remission; OS, overall survival; EFS, event-free survival; * <em>P</em>&lt;0.05</p></div></div></section><p id="Par22">Thirty-two patients received a median of 2 (IQR, 1-2.5) cycles of consolidation chemotherapy after CRc. In the sorafenib group, 25 patients with CRc received sorafenib maintenance for a median duration of 421 days (IQR, 343 to 617) after CRc. The median relative dose intensity of sorafenib maintenance was 400 (IQR, 400–800) mg/day. Eight of the 25 patients with CRc received sorafenib combined with interferon-ɑ (IFN-ɑ) as maintenance therapy. IFN-ɑ was administered subcutaneously at a dosage of 3 million units 2–3 times per week. The median duration of IFN-ɑ maintenance was 165 (IQR, 97.5 to 225) days. One patient in the sorafenib group received a second allo-HSCT after achieving CR. One patient in the non-sorafenib group proceeded to a second allo-HSCT after achieving PR.</p>
<p id="Par23">Of the 32 patients who achieved CRc after salvage therapy, 9 experienced re-relapse, including 6 in the sorafenib group and 3 in the non-sorafenib group. In the sorafenib group, 19 patients remained in CRc, 3 patients re-relapsed during sorafenib maintenance after CRc, and 3 patients re-relapsed at 3, 5, and 12 months after sorafenib was discontinued. The leukemia re-relapse rate did not differ significantly between sorafenib and non-sorafenib groups (15.8% vs. 12.5%, <em>P</em> = 0.898).</p></section><section id="Sec10"><h3 class="pmc_sec_title">Survival</h3>
<p id="Par24">With a median follow-up of 13.2 months (IQR, 3.2–43.5) after relapse, 18 patients were living and 44 deceased. Causes of death included leukemia progression (<em>n</em> = 34), infections (<em>n</em> = 9) and GVHD (<em>n</em> = 1). The 2-year OS and EFS were 35.5% (95% CI, 25.4%-49.6%) and 33.9% (23.9%-48.0%), respectively. The 2-year OS was 47.4% (95%CI, 33.9%-66.2%) for patients in the sorafenib group and 16.7% (6.8%-40.8%) in the non-sorafenib group (HR = 0.484, 95% CI: 0.265–0.885; <em>P</em> = 0.006; Fig. <a href="#Fig2" class="usa-link">2</a>A); median OS was 18.4 months (95% CI, 0-50.8) and 4.8 months (2.0-7.6) in the sorafenib and non-sorafenib groups (Table <a href="#Tab2" class="usa-link">2</a>). The 2-year EFS was 44.7% (31.4%-63.7%) for patients in the sorafenib group and 16.7% (6.8%-40.8%) in the non-sorafenib group, respectively (HR = 0.511, 95% CI: 0.282–0.925; <em>P</em> = 0.012; Fig. <a href="#Fig2" class="usa-link">2</a>B); median EFS was 11.4 months (95% CI, 0-29.2) and 2.3 months (0.2–4.3) in the sorafenib and non-sorafenib groups (Table <a href="#Tab2" class="usa-link">2</a>). Forest plot for univariable analysis of OS and EFS is shown in Fig. <a href="#Fig3" class="usa-link">3</a>. The 2-year OS and EFS were 51.5% (95%CI, 37.0%-71.7%) and 48.5% (34.1%-68.9%) for patients in the group of sorafenib combined with chemotherapy and DLI, and 17.2% (7.8%-38.3%) and 17.2% (7.8%-38.3%) for patients in the other three groups, respectively (<em>P</em> = 0.003, <em>P</em> = 0.006). The 2-year OS was 51.5% (95%CI, 37.0%-71.7%) in the group of sorafenib combined with chemotherapy and DLI, and 20.0% (3.5%-100.0%) in the group of sorafenib combined with chemotherapy (<em>P</em> = 0.046). The 2-year EFS was 48.5% (34.1%-68.9%) and 20.0% (3.5%-100.0%) in the two groups (<em>P</em> = 0.035).</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366021_40364_2025_816_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e708/12366021/fbb6fde27fdd/40364_2025_816_Fig2_HTML.jpg" loading="lazy" id="d33e1034" height="702" width="669" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>The outcomes of patients who relapsed post-transplant receiving salvage therapy with or without sorafenib. OS (<strong>A</strong>) and EFS (<strong>B</strong>) between the sorafenib and non-sorafenib groups</p></figcaption></figure><figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366021_40364_2025_816_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e708/12366021/f5382d956610/40364_2025_816_Fig3_HTML.jpg" loading="lazy" id="d33e1051" height="658" width="669" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Forest plot for univariable analysis of overall survival (<strong>A</strong>) and event-free survival (<strong>B</strong>). CRc, composite complete remission; NR, no response; MSD, HLA-matched sibling donor; HID, HLA-haploidentical related donor; DLI, donor lymphocyte infusion; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease</p></figcaption></figure><p id="Par27">Multivariable analysis revealed that salvage therapy including sorafenib and CRc at transplant were protective factors for longer OS (HR = 0.395, 95% CI: 0.209–0.746, <em>P</em> = 0.004; HR = 0.493, 95% CI: 0.244–0.994, <em>P</em> = 0.048). Salvage therapy including sorafenib was a protective factor for longer EFS (HR = 0.406, 95% CI: 0.218–0.754, <em>P</em> = 0.004) (Table <a href="#Tab3" class="usa-link">3</a>).</p>
<section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Univariable and multivariable analyses for the risk factors of survival</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" rowspan="2" colspan="1">Parameters</th>
<th align="left" colspan="3" rowspan="1">OS</th>
<th align="left" colspan="3" rowspan="1">EFS</th>
<th align="left" colspan="1" rowspan="1"></th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">Univariable<br>HR (95%CI); <em>P</em>
</th>
<th align="left" colspan="1" rowspan="1">Multivariable<br>HR (95%CI); <em>P</em>
</th>
<th align="left" colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1">Univariable<br>HR (95%CI); <em>P</em>
</th>
<th align="left" colspan="1" rowspan="1">Multivariable<br>HR (95%CI); <em>P</em>
</th>
<th align="left" colspan="2" rowspan="1"></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>Gender</p>
<p> male vs. female</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>1.428 (0.772–2.642);</p>
<p>0.257</p>
</td>
<td align="left" colspan="2" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">
<p>1.405 (0.763–2.588);</p>
<p>0.275</p>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>-</strong>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>Patient’s age</p>
<p> &lt; 35.5 vs. ≥ 35.5 years (median)</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>0.925 (0.511–1.675);</p>
<p>0.797</p>
</td>
<td align="left" colspan="2" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">
<p>0.960 (0.534–1.725);</p>
<p>0.891</p>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>-</strong>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>Disease status at transplant</p>
<p> CRc vs. NR</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>0.438 (0.234–0.821);</p>
<p>*0.010</p>
</td>
<td align="left" colspan="2" rowspan="1">
<p>0.493 (0.244–0.994)</p>
<p>*0.048</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>0.449 (0.241–0.839);</p>
<p>*0.012</p>
</td>
<td align="left" colspan="2" rowspan="1">
<p>0.566 (0.283–1.131);</p>
<p>0.089</p>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Donor type</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="2" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="2" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p> HLA-matched sibling vs.</p>
<p> HLA-haploidentical related</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>0.930 (0.691–1.253);</p>
<p>0.634</p>
</td>
<td align="left" colspan="2" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">
<p>0.912 (0.680–1.223);</p>
<p>0.539</p>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>-</strong>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ELN classification<sup>#</sup>
</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="2" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="2" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Adverse</td>
<td align="left" colspan="1" rowspan="1">Reference</td>
<td align="left" colspan="2" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">Reference</td>
<td align="left" colspan="2" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Intermediate</td>
<td align="left" colspan="1" rowspan="1">
<p>0.600 (0.278–1.297);</p>
<p>0.194</p>
</td>
<td align="left" colspan="2" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">
<p>0.557 (0.257–1.207);</p>
<p>0.138</p>
</td>
<td align="left" colspan="2" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Favorable</td>
<td align="left" colspan="1" rowspan="1">
<p>0.427 (0.102–1.780);</p>
<p>0.243</p>
</td>
<td align="left" colspan="2" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">
<p>0.405 (0.097–1.691);</p>
<p>0.215</p>
</td>
<td align="left" colspan="2" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Relapse type post-transplant</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="2" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="2" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Hematologic</td>
<td align="left" colspan="1" rowspan="1">Reference</td>
<td align="left" colspan="2" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">Reference</td>
<td align="left" colspan="2" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Extramedullary</td>
<td align="left" colspan="1" rowspan="1">
<p>0.257 (0.061–1.072);</p>
<p>0.062</p>
</td>
<td align="left" colspan="2" rowspan="1">
<p>0.291 (0.065-1.300);</p>
<p>0.106</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>0.229 (0.055–0.952);</p>
<p>*0.043</p>
</td>
<td align="left" colspan="2" rowspan="1">
<p>0.287 (0.065–1.269);</p>
<p>0.100</p>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Hematologic + extramedullary</td>
<td align="left" colspan="1" rowspan="1">
<p>0.699 (0.292–1.670);</p>
<p>0.420</p>
</td>
<td align="left" colspan="2" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">
<p>0.716 (0.301–1.705);</p>
<p>0.451</p>
</td>
<td align="left" colspan="2" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>Relapse time post-transplant</p>
<p> ≥6 months vs.&lt;6 months</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>0.501 (0.274–0.916);</p>
<p>*0.025</p>
</td>
<td align="left" colspan="2" rowspan="1">
<p>0.778 (0.396–1.532);</p>
<p>0.468</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>0.442 (0.243–0.804);</p>
<p>*0.007</p>
</td>
<td align="left" colspan="2" rowspan="1">
<p>0.611 (0.313–1.195);</p>
<p>0.150</p>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>Salvage therapy including sorafenib </p>
<p> Sorafenib vs. no sorafenib</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>0.484 (0.265–0.885);</p>
<p>*0.018</p>
</td>
<td align="left" colspan="2" rowspan="1">
<p>0.395 (0.209–0.746);</p>
<p>*0.004</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>0.511 (0.282–0.925);</p>
<p>*0.027</p>
</td>
<td align="left" colspan="2" rowspan="1">
<p>0.406 (0.218–0.754);</p>
<p>*0.004</p>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>Salvage therapy including DLI</p>
<p> DLI vs. no DLI</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>0.627 (0.308–1.274);</p>
<p>0.197</p>
</td>
<td align="left" colspan="2" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">
<p>0.642 (0.317-1.300);</p>
<p>0.218</p>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>-</strong>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>aGVHD after salvage therapy</p>
<p> aGVHD vs. no aGVHD</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>0.805 (0.406–1.595);</p>
<p>0.534</p>
</td>
<td align="left" colspan="2" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">
<p>1.021 (0.527–1.979);</p>
<p>0.950</p>
</td>
<td align="left" colspan="2" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>cGVHD after salvage therapy</p>
<p> cGVHD vs. no cGVHD</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>0.549 (0.264–1.145);</p>
<p>0.110</p>
</td>
<td align="left" colspan="2" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">
<p>0.555 (0.267–1.154);</p>
<p>0.115</p>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>-</strong>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p135"><p>Abbreviations: OS, overall survival; EFS, event-free survival; HR, hazard ratios; CI, confidence interval; CRc, composite complete remission; NR, no response; DLI, donor lymphocyte infusion; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; * <em>P</em>&lt;0.05. <sup>#</sup>referred to 2022 European Leukemia Net risk stratification</p></div></div></section><p id="Par29">Of the 62 AML patients, 43 patients were assessed for mutations at relapse post-transplant. The genetic landscape of the 43 patients at diagnosis and at relapse is shown in Fig. <a href="#Fig4" class="usa-link">4</a>. Overall, 30 (69.8%) of the 43 evaluable relapsed patients had new gene mutations at relapse. The top three types of new mutations detected were activated signaling (13 patients, 30.2%), chromatin modifiers (13 patients, 30.2%) and DNA methylation (11 patients, 25.6%), respectively. The most frequently genes in new mutations were TET2 (6 patients, 14.0%), NRAS (5 patients, 11.6%) and TET1 (5 patients, 11.6%).</p>
<figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366021_40364_2025_816_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e708/12366021/ff87b0e8be36/40364_2025_816_Fig4_HTML.jpg" loading="lazy" id="d33e1412" height="1015" width="752" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Mutations detected at diagnosis and at relapse in patients who relapsed post-transplant. OS, overall survival</p></figcaption></figure></section><section id="Sec11"><h3 class="pmc_sec_title">Adverse events (AEs)</h3>
<p id="Par31">Because systemic chemotherapy might cause cytopenia, hematological AEs were not analyzed in this study. With a median of 14 days (range, 5–63 days) after sorafenib initiation, 15 patients (39.5%) experienced treatment-related AEs, including rash (<em>n</em> = 6), hand-foot-skin reaction (<em>n</em> = 4), diarrhea (<em>n</em> = 3), hypertension (<em>n</em> = 1), and abnormal liver enzymes (<em>n</em> = 1). Seven patients required sorafenib dose modifications because of AEs, including 5 dose reductions and 2 dose interruptions. With sorafenib dose modifications and symptomatic treatment, AEs were controlled and patients were re-administered sorafenib.</p>
<p id="Par32">Nineteen patients developed aGVHD (grade I, <em>n</em> = 6; grade II, <em>n</em> = 10; grade III, <em>n</em> = 2; grade IV, <em>n</em> = 1), and 13 had cGVHD (local, <em>n</em> = 9; extensive, <em>n</em> = 4) before relapse. The 100-day cumulative incidence of aGVHD before relapse was 30.6% (95% CI, 19.6% -42.4%), and the 2-year cumulative incidence of cGVHD before relapse was 21.0% (11.8%-32.0%). Seventeen patients developed aGVHD (grade I, <em>n</em> = 7; grade II, <em>n</em> = 7; grade III, <em>n</em> = 2; grade IV, <em>n</em> = 1), and 16 had cGVHD (local, <em>n</em> = 11; extensive, <em>n</em> = 5) after salvage therapy. The 100-day cumulative incidence of aGVHD after salvage therapy was 27.4% (95% CI, 16.9%-39.0%), and the 2-year cumulative incidence of cGVHD was 21.4% (12.0%-32.7%), respectively. The incidences of aGVHD and cGVHD were similar between the patients in the sorafenib and non-sorafenib groups (<em>P</em> = 0.806, <em>P</em> = 0.908). The incidences of aGVHD and cGVHD did not differ significantly between the patients undergoing and those not undergoing DLI (<em>P</em> = 0.408, <em>P</em> = 0.359). The mortality of GVHD after salvage therapy was 1.6% (95% CI, 0.3%-8.6%).</p></section></section><section id="Sec12"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par33">The prognosis of AML patients with FLT3 wild-type relapsing after allo-HSCT is dismal [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>–<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>]. Until now, there has been no standard approach to solve this difficult clinical problem. Multi-kinase inhibitor sorafenib has been used in a variety of settings for FLT3-ITD AML, including induction, post-remission maintenance, and salvage therapy [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>–<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>, <a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>, <a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>]. Recent studies including our previous phase 2 trial have demonstrated that use of sorafenib might benefit AML patients with FLT3 wild-type [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>, <a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>, <a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>, <a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. Currently, there is a lack of studies on the use of sorafenib in AML patients with FLT3 wild-type who relapse after allo-HSCT. In this exploratory study, we compared the efficacy of salvage therapy with and without sorafenib in AML patients with FLT3 wild-type relapsing after allo-HSCT, and found that salvage therapy containing sorafenib was superior to that without sorafenib with respect to response rates and survival. Twenty-five (65.8%) of the 38 patients in the sorafenib group achieved CRc, and the 2-year OS was 47.4%. For patients who relapsed after allo-HSCT, the CRc rate was reported ranging from 15 to 47% after conventional therapies, with the 2-year OS of only 26% [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>, <a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>, <a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>]. Our results of CRc and OS were superior to those reported in the literature [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>, <a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>, <a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>], although comparisons between different trials required to be made with caution. The superior efficacy might be attributed to the synergistic effect of sorafenib, chemotherapy and DLI to achieve a higher CRc rate and deep remission, as well as the superior OS obtained from post-remission maintenance therapy with sorafenib, consolidation chemotherapy and IFN-ɑ.</p>
<p id="Par34">Except for blocking multiple pathways involved in the development of AML, sorafenib might also exert anti-leukemic effects through immune pathways [<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>, <a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>, <a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>]. Mathew et al. reported that sorafenib promoted GVL activity in mice and humans through interleukin-15 (IL-15) production in FLT3-ITD-mutant leukemia cells, resulting in activation of the IRF7-IL-15 axis and metabolic reprogramming of leukemia-reactive T cells [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>]. In this study, sorafenib therapy was associated with improved outcomes for AML patients with FLT3 wild-type relapsing after allo-HSCT and the incidences of acute and chronic GVHD did not differ between patients with and without sorafenib. These results suggested that the effects of sorafenib were at least in part related to off-target immunomodulatory activity, and sorafenib inducing GVL effects might be independent of GVHD. The underlying mechanism requires further investigation. Besides, to evaluate the efficacy of sorafenib on FLT3-negative acute leukemia, we are doing a multi-center, randomized, phase 3 trial of sorafenib maintenance after allo-HSCT in patients with FLT3-negative acute leukemia (<a href="https://clinicaltrials.gov/ct2/show/NCT04674345" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04674345</a>).</p>
<p id="Par35">DLI is often associated with a high incidence and mortality of GVHD [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>–<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>]. The incidences of aGVHD and cGVHD after DLI are reported to be 18.2%-56.9% and 16.6%-48.3%, respectively [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>–<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>]. Whether the use of sorafenib post-transplantation increases GVHD is inconclusive [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>, <a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>, <a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>]. In the current study, salvage therapy mainly included sorafenib combined with chemotherapy and DLI, and the incidences of aGVHD and cGVHD after salvage therapy were 27.4% and 21.4%. Our results were consistent with most literature reports about DLI [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>–<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>], suggesting that sorafenib combined with DLI did not increase the risk of GVHD compared with DLI. These results suggested that our salvage therapy strategy was safe and welltolerated for AML patients with FLT3 wild-type who relapsed after allo-HSCT.</p>
<p id="Par36">Our study had a few limitations. First, due to the retrospective study, the heterogeneity of the population including several centers and inherent selection bias was inevitable. Well-designed prospective clinical trials are needed to establish the optimal therapy for these relapsed patients. Second, the number of patients was relatively small, and some patients were followed for a short time, which might affect the accuracy of our results.</p>
<p id="Par37">In conclusion, salvage therapy including sorafenib and DLI is associated with improved outcomes for AML patients with FLT3 wild-type who relapse after allo-HSCT. Sorafenib combined with chemotherapy and DLI could be a therapeutic option for FLT3 wild-type AML relapsing after allo-HSCT.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>We thank the patients, their families and their caregivers involved in the trial.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations </h2>
<dl class="def-list">
<dt>AE</dt>
<dd><p id="Par41">Adverse event</p></dd>
<dt>aGVHD</dt>
<dd><p id="Par42">Acute graft-versus-host disease</p></dd>
<dt>allo-HSCT</dt>
<dd><p id="Par43">Allogeneic hematopoietic stem cell transplantation</p></dd>
<dt>AML</dt>
<dd><p id="Par44">Acute myeloid leukemia</p></dd>
<dt>BM</dt>
<dd><p id="Par45">Bone marrow</p></dd>
<dt>cGVHD</dt>
<dd><p id="Par46">Chronic graft-versus-host disease</p></dd>
<dt>CI</dt>
<dd><p id="Par47">Confidence interval</p></dd>
<dt>CR</dt>
<dd><p id="Par48">Complete remission</p></dd>
<dt>CRc</dt>
<dd><p id="Par49">Composite complete remission</p></dd>
<dt>CRi</dt>
<dd><p id="Par50">Complete remission with incomplete hematological recovery</p></dd>
<dt>DAC-CAG</dt>
<dd><p id="Par51">Decitabine, aclacinomycin, cytarabine and granulocyte colony-stimulating factor regimen</p></dd>
<dt>DLI</dt>
<dd><p id="Par52">Donor lymphocyte infusion</p></dd>
<dt>EFS</dt>
<dd><p id="Par53">Event-free survival</p></dd>
<dt>ELN</dt>
<dd><p id="Par54">European leukemia net</p></dd>
<dt>FLT3-ITD FLT3</dt>
<dd><p id="Par55">Internal tandem duplication</p></dd>
<dt>G-CSF</dt>
<dd><p id="Par56">Granulocyte colony-stimulating factor</p></dd>
<dt>GVHD</dt>
<dd><p id="Par57">Graft-versus-host disease</p></dd>
<dt>GVL</dt>
<dd><p id="Par58">Graft-versus-leukemia</p></dd>
<dt>HR</dt>
<dd><p id="Par59">Hazard ratios</p></dd>
<dt>IFN-ɑ</dt>
<dd><p id="Par60">Interferon-ɑ</p></dd>
<dt>IL-15</dt>
<dd><p id="Par61">Interleukin-15</p></dd>
<dt>IQR</dt>
<dd><p id="Par62">Interquartile range</p></dd>
<dt>MFC</dt>
<dd><p id="Par63">Multi-parameter flow cytometry</p></dd>
<dt>MRD</dt>
<dd><p id="Par64">Measurable residual disease</p></dd>
<dt>NR</dt>
<dd><p id="Par65">Non-remission</p></dd>
<dt>OS</dt>
<dd><p id="Par66">Overall survival</p></dd>
<dt>PCR</dt>
<dd><p id="Par67">Polymerase chain reaction</p></dd>
<dt>VA</dt>
<dd><p id="Par68">Venetoclax and azacytidine</p></dd>
<dt>VAH</dt>
<dd><p id="Par69">Venetoclax, homoharringtonine and azacytidine</p></dd>
</dl></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>LX and QFL were responsible for the conception and design. ZHJ, YZ, YXB, FD, MLF and TZ coordinated the data collection, analyzed data, and wrote the manuscript; DNN, YXZ, YRJ, PZ, ZPF, NX, FH, RL, MD, XJX, ZKL, HJ and JS contributed genetic and clinical patient data; LX, QFL, ZHJ, YZ, YXB, FD and TZ were responsible for the writing, review, and/or revision of the manuscript. All authors read and approved the final manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>This work was supported by National Natural Science Foundation of China (No. 82370216, 82170213), National Key Research and Development Program (No. 2022YFC2502600-5, 2021YFC2500300-4), Natural Science Foundation of Guangdong Province (No. 2024A1515010794), Science and Technology Program of Guangdong Province (No. 2023B110007), Guangzhou Science and Technology Program (No. 2023A04J2327), and Clinical Research Program of Nanfang Hospital, Southern Medical University (No. 2021CR002).</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>The data that support the findings of this study are available from the corresponding author at 356135708@qq.com upon reasonable request.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Ethics approval and consent to participate</h3>
<p id="Par38">The trial was first approved by Medical Ethics Committee of Nanfang Hospital of Southern Medical University. Subsequently, the remaining four centers conducted ethical filing. This trial was reviewed and approved by the ethics committee review board at each participating center and was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all the patients.</p></section><section id="FPar2"><h3 class="pmc_sec_title">Consent for publication</h3>
<p id="Par39">Not applicable.</p></section><section id="FPar3"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par40">The authors declare no competing interests.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn1">
<p><strong>Publisher’s note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div>
<div class="fn p" id="fn2"><p>Zhonghui Jiang, Ya Zhou, Yuxin Bai, Fang Dai, Menglin Fan and Tian Zhang contributed equally to this work.</p></div>
</div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Qifa Liu, Email: liuqifa628@163.com.</p>
<p>Li Xuan, Email: 356135708@qq.com.</p></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Wang Y, Chang YJ, Chen J, Han M, Hu J, Hu J, et al. Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic Haematopoietic stem cell transplantation in china: 2024 update. Cancer Lett. 2024;605:217264.
</cite> [<a href="https://doi.org/10.1016/j.canlet.2024.217264" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39332587/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20Y,%20Chang%20YJ,%20Chen%20J,%20Han%20M,%20Hu%20J,%20Hu%20J,%20et%20al.%20Consensus%20on%20the%20monitoring,%20treatment,%20and%20prevention%20of%20leukaemia%20relapse%20after%20allogeneic%20Haematopoietic%20stem%20cell%20transplantation%20in%20china:%202024%20update.%20Cancer%20Lett.%202024;605:217264." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Bazarbachi A, Schmid C, Labopin M, Beelen D, Wolfgang BI, Potter V, et al. Evaluation of trends and prognosis over time in patients with AML relapsing after allogeneic hematopoietic cell transplant reveals improved survival for young patients in recent years. Clin Cancer Res. 2020;26(24):6475–82.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-20-3134" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32988970/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bazarbachi%20A,%20Schmid%20C,%20Labopin%20M,%20Beelen%20D,%20Wolfgang%20BI,%20Potter%20V,%20et%20al.%20Evaluation%20of%20trends%20and%20prognosis%20over%20time%20in%20patients%20with%20AML%20relapsing%20after%20allogeneic%20hematopoietic%20cell%20transplant%20reveals%20improved%20survival%20for%20young%20patients%20in%20recent%20years.%20Clin%20Cancer%20Res.%202020;26(24):6475%E2%80%9382." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>de Lima M, Porter DL, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, et al. Proceedings from the National cancer institute’s second international workshop on the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transpl. 2014;20(1):4–13.</cite> [<a href="https://doi.org/10.1016/j.bbmt.2013.08.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3938421/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24018392/" class="usa-link">PubMed</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, et al. Addition of Sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16(16):1691–99.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(15)00362-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26549589/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?R%C3%B6llig%20C,%20Serve%20H,%20H%C3%BCttmann%20A,%20Noppeney%20R,%20M%C3%BCller-Tidow%20C,%20Krug%20U,%20et%20al.%20Addition%20of%20Sorafenib%20versus%20placebo%20to%20standard%20therapy%20in%20patients%20aged%2060%20years%20or%20younger%20with%20newly%20diagnosed%20acute%20myeloid%20leukaemia%20(SORAML):%20a%20multicentre,%20phase%202,%20randomised%20controlled%20trial.%20Lancet%20Oncol.%202015;16(16):1691%E2%80%9399." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Xuan L, Wang Y, Huang F, Jiang E, Deng L, Wu B, et al. Effect of Sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation. Cancer. 2018;124(9):1954–63.
</cite> [<a href="https://doi.org/10.1002/cncr.31295" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29509276/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xuan%20L,%20Wang%20Y,%20Huang%20F,%20Jiang%20E,%20Deng%20L,%20Wu%20B,%20et%20al.%20Effect%20of%20Sorafenib%20on%20the%20outcomes%20of%20patients%20with%20FLT3-ITD%20acute%20myeloid%20leukemia%20undergoing%20allogeneic%20hematopoietic%20stem%20cell%20transplantation.%20Cancer.%202018;124(9):1954%E2%80%9363." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Xuan L, Wang Y, Chen J, Jiang E, Gao L, Wu B, et al. Sorafenib therapy is associated with improved outcomes for FMS-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2019;25(8):1674–81.</cite> [<a href="https://doi.org/10.1016/j.bbmt.2019.04.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31009704/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xuan%20L,%20Wang%20Y,%20Chen%20J,%20Jiang%20E,%20Gao%20L,%20Wu%20B,%20et%20al.%20Sorafenib%20therapy%20is%20associated%20with%20improved%20outcomes%20for%20FMS-like%20tyrosine%20kinase%203%20internal%20tandem%20duplication%20acute%20myeloid%20leukemia%20relapsing%20after%20allogeneic%20hematopoietic%20stem%20cell%20transplantation.%20Biol%20Blood%20Marrow%20Transpl.%202019;25(8):1674%E2%80%9381." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Antar AI, Otrock ZK, Jabbour E, Mohty M, Bazarbachi A. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. Leukemia. 2020;34(3):682–96.
</cite> [<a href="https://doi.org/10.1038/s41375-019-0694-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31919472/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Antar%20AI,%20Otrock%20ZK,%20Jabbour%20E,%20Mohty%20M,%20Bazarbachi%20A.%20FLT3%20inhibitors%20in%20acute%20myeloid%20leukemia:%20ten%20frequently%20asked%20questions.%20Leukemia.%202020;34(3):682%E2%80%9396." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Röllig C, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-Internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993–3002.
</cite> [<a href="https://doi.org/10.1200/JCO.19.03345" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32673171/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Burchert%20A,%20Bug%20G,%20Fritz%20LV,%20Finke%20J,%20Stelljes%20M,%20R%C3%B6llig%20C,%20et%20al.%20Sorafenib%20maintenance%20after%20allogeneic%20hematopoietic%20stem%20cell%20transplantation%20for%20acute%20myeloid%20leukemia%20with%20FLT3-Internal%20tandem%20duplication%20mutation%20(SORMAIN).%20J%20Clin%20Oncol.%202020;38(26):2993%E2%80%933002." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic Haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21(9):1201–12.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(20)30455-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32791048/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xuan%20L,%20Wang%20Y,%20Huang%20F,%20Fan%20Z,%20Xu%20Y,%20Sun%20J,%20et%20al.%20Sorafenib%20maintenance%20in%20patients%20with%20FLT3-ITD%20acute%20myeloid%20leukaemia%20undergoing%20allogeneic%20Haematopoietic%20stem-cell%20transplantation:%20an%20open-label,%20multicentre,%20randomised%20phase%203%20trial.%20Lancet%20Oncol.%202020;21(9):1201%E2%80%9312." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Xuan L, Wang Y, Yang K, Shao R, Huang F, Fan Z, et al. Sorafenib maintenance after allogeneic Haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023;10(8):e600–11.
</cite> [<a href="https://doi.org/10.1016/S2352-3026(23)00117-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37414062/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xuan%20L,%20Wang%20Y,%20Yang%20K,%20Shao%20R,%20Huang%20F,%20Fan%20Z,%20et%20al.%20Sorafenib%20maintenance%20after%20allogeneic%20Haemopoietic%20stem-cell%20transplantation%20in%20patients%20with%20FLT3-ITD%20acute%20myeloid%20leukaemia:%20long-term%20follow-up%20of%20an%20open-label,%20multicentre,%20randomised,%20phase%203%20trial.%20Lancet%20Haematol.%202023;10(8):e600%E2%80%9311." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Halpern AB, Rodríguez-Arbolí E, Othus M, Garcia KA, Percival MM, Cassaday RD, et al. Phase 1/2 study of Sorafenib added to cladribine, high-dose cytarabine, G-CSF, and Mitoxantrone in untreated AML. Blood Adv. 2023;7(17):4950–61.
</cite> [<a href="https://doi.org/10.1182/bloodadvances.2023010392" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10463192/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37339483/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Halpern%20AB,%20Rodr%C3%ADguez-Arbol%C3%AD%20E,%20Othus%20M,%20Garcia%20KA,%20Percival%20MM,%20Cassaday%20RD,%20et%20al.%20Phase%201/2%20study%20of%20Sorafenib%20added%20to%20cladribine,%20high-dose%20cytarabine,%20G-CSF,%20and%20Mitoxantrone%20in%20untreated%20AML.%20Blood%20Adv.%202023;7(17):4950%E2%80%9361." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Röllig C, Serve H, Noppeney R, Hanoun M, Krug U, Baldus CD, et al. Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. Leukemia. 2021;35(9):2517–25.
</cite> [<a href="https://doi.org/10.1038/s41375-021-01148-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8410595/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33603142/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?R%C3%B6llig%20C,%20Serve%20H,%20Noppeney%20R,%20Hanoun%20M,%20Krug%20U,%20Baldus%20CD,%20et%20al.%20Sorafenib%20or%20placebo%20in%20patients%20with%20newly%20diagnosed%20acute%20myeloid%20leukaemia:%20long-term%20follow-up%20of%20the%20randomized%20controlled%20SORAML%20trial.%20Leukemia.%202021;35(9):2517%E2%80%9325." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Yu S, Zhang Y, Yu G, Wang Y, Shao R, Du X, et al. Sorafenib plus triplet therapy with venetoclax, Azacitidine and Homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study. J Intern Med. 2024;295(2):216–28.
</cite> [<a href="https://doi.org/10.1111/joim.13738" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37899297/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yu%20S,%20Zhang%20Y,%20Yu%20G,%20Wang%20Y,%20Shao%20R,%20Du%20X,%20et%20al.%20Sorafenib%20plus%20triplet%20therapy%20with%20venetoclax,%20Azacitidine%20and%20Homoharringtonine%20for%20refractory/relapsed%20acute%20myeloid%20leukemia%20with%20FLT3-ITD:%20A%20multicenter%20phase%202%20study.%20J%20Intern%20Med.%202024;295(2):216%E2%80%9328." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023;16(1):29.
</cite> [<a href="https://doi.org/10.1186/s13045-023-01424-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10039574/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36966300/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bhansali%20RS,%20Pratz%20KW,%20Lai%20C.%20Recent%20advances%20in%20targeted%20therapies%20in%20acute%20myeloid%20leukemia.%20J%20Hematol%20Oncol.%202023;16(1):29." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Döhner H, Wei AH, Appelbaum FR, Craddock C, Dinardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–77.
</cite> [<a href="https://doi.org/10.1182/blood.2022016867" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35797463/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?D%C3%B6hner%20H,%20Wei%20AH,%20Appelbaum%20FR,%20Craddock%20C,%20Dinardo%20CD,%20Dombret%20H,%20et%20al.%20Diagnosis%20and%20management%20of%20AML%20in%20adults:%202022%20recommendations%20from%20an%20international%20expert%20panel%20on%20behalf%20of%20the%20ELN.%20Blood.%202022;140(12):1345%E2%80%9377." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>National Comprehensive Cancer Network. Acute Myeloid Leukemia (version 2). 2025; <a href="https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf</a></cite> [<a href="https://doi.org/10.6004/jnccn.2013.0127" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4161234/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24029121/" class="usa-link">PubMed</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Mathew NR, Baumgartner F, Braun L, O’Sullivan D, Thomas S, Waterhouse M, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018;24(3):282–91.
</cite> [<a href="https://doi.org/10.1038/nm.4484" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6029618/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29431743/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mathew%20NR,%20Baumgartner%20F,%20Braun%20L,%20O%E2%80%99Sullivan%20D,%20Thomas%20S,%20Waterhouse%20M,%20et%20al.%20Sorafenib%20promotes%20graft-versus-leukemia%20activity%20in%20mice%20and%20humans%20through%20IL-15%20production%20in%20FLT3-ITD-mutant%20leukemia%20cells.%20Nat%20Med.%202018;24(3):282%E2%80%9391." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Hage C, Hoves S, Strauss L, Bissinger S, Prinz Y, Pöschinger T, et al. Sorafenib induces pyroptosis in macrophages and triggers natural killer Cell-Mediated cytotoxicity against hepatocellular carcinoma. Hepatology. 2019;70(4):1280–97.
</cite> [<a href="https://doi.org/10.1002/hep.30666" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31002440/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hage%20C,%20Hoves%20S,%20Strauss%20L,%20Bissinger%20S,%20Prinz%20Y,%20P%C3%B6schinger%20T,%20et%20al.%20Sorafenib%20induces%20pyroptosis%20in%20macrophages%20and%20triggers%20natural%20killer%20Cell-Mediated%20cytotoxicity%20against%20hepatocellular%20carcinoma.%20Hepatology.%202019;70(4):1280%E2%80%9397." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825–28.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/7581076/" class="usa-link">PubMed</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11(12):945–56.</cite> [<a href="https://doi.org/10.1016/j.bbmt.2005.09.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16338616/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Filipovich%20AH,%20Weisdorf%20D,%20Pavletic%20S,%20Socie%20G,%20Wingard%20JR,%20Lee%20SJ,%20et%20al.%20National%20institutes%20of%20health%20consensus%20development%20project%20on%20criteria%20for%20clinical%20trials%20in%20chronic%20graft-versus-host%20disease:%20I.%20Diagnosis%20and%20staging%20working%20group%20report.%20Biol%20Blood%20Marrow%20Transpl.%202005;11(12):945%E2%80%9356." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36(27):4391–400.
</cite> [<a href="https://doi.org/10.1002/sim.7501" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5698744/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28913837/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Austin%20PC,%20Fine%20JP.%20Practical%20recommendations%20for%20reporting%20Fine-Gray%20model%20analyses%20for%20competing%20risk%20data.%20Stat%20Med.%202017;36(27):4391%E2%80%93400." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Chen X, Huang J, Xu N, Fan Z, Nie D, Huang F, et al. A phase 2 study of Sorafenib combined with conventional therapies in refractory central nervous system leukemia. Cancer. 2022;128(11):2138–47.
</cite> [<a href="https://doi.org/10.1002/cncr.34182" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35315510/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20X,%20Huang%20J,%20Xu%20N,%20Fan%20Z,%20Nie%20D,%20Huang%20F,%20et%20al.%20A%20phase%202%20study%20of%20Sorafenib%20combined%20with%20conventional%20therapies%20in%20refractory%20central%20nervous%20system%20leukemia.%20Cancer.%202022;128(11):2138%E2%80%9347." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Bejanyan N, Weisdorf DJ, Logan BR, Wang HL, Devine SM, de Lima M, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transpl. 2015;21(3):454–59.</cite> [<a href="https://doi.org/10.1016/j.bbmt.2014.11.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4329076/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25460355/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bejanyan%20N,%20Weisdorf%20DJ,%20Logan%20BR,%20Wang%20HL,%20Devine%20SM,%20de%20Lima%20M,%20et%20al.%20Survival%20of%20patients%20with%20acute%20myeloid%20leukemia%20relapsing%20after%20allogeneic%20hematopoietic%20cell%20transplantation:%20a%20center%20for%20international%20blood%20and%20marrow%20transplant%20research%20study.%20Biol%20Blood%20Marrow%20Transpl.%202015;21(3):454%E2%80%9359." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 2013;27(6):1229–35.
</cite> [<a href="https://doi.org/10.1038/leu.2013.7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23314834/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Schroeder%20T,%20Czibere%20A,%20Platzbecker%20U,%20Bug%20G,%20Uharek%20L,%20Luft%20T,%20et%20al.%20Azacitidine%20and%20donor%20lymphocyte%20infusions%20as%20first%20salvage%20therapy%20for%20relapse%20of%20AML%20or%20MDS%20after%20allogeneic%20stem%20cell%20transplantation.%20Leukemia.%202013;27(6):1229%E2%80%9335." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R, et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic Stem-Cell transplantation. J Clin Oncol. 2002;20(2):405–12.
</cite> [<a href="https://doi.org/10.1200/JCO.2002.20.2.405" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11786567/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Levine%20JE,%20Braun%20T,%20Penza%20SL,%20Beatty%20P,%20Cornetta%20K,%20Martino%20R,%20et%20al.%20Prospective%20trial%20of%20chemotherapy%20and%20donor%20leukocyte%20infusions%20for%20relapse%20of%20advanced%20myeloid%20malignancies%20after%20allogeneic%20Stem-Cell%20transplantation.%20J%20Clin%20Oncol.%202002;20(2):405%E2%80%9312." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Schmid C, Labopin M, Nagler A, Bornhäuser M, Finke J, Fassas A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party. J Clin Oncol. 2007;25(31):4938–45.
</cite> [<a href="https://doi.org/10.1200/JCO.2007.11.6053" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17909197/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Schmid%20C,%20Labopin%20M,%20Nagler%20A,%20Bornh%C3%A4user%20M,%20Finke%20J,%20Fassas%20A,%20et%20al.%20Donor%20lymphocyte%20infusion%20in%20the%20treatment%20of%20first%20hematological%20relapse%20after%20allogeneic%20stem-cell%20transplantation%20in%20adults%20with%20acute%20myeloid%20leukemia:%20a%20retrospective%20risk%20factors%20analysis%20and%20comparison%20with%20other%20strategies%20by%20the%20EBMT%20acute%20leukemia%20working%20party.%20J%20Clin%20Oncol.%202007;25(31):4938%E2%80%9345." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Chen YB, Li S, Lane AA, Connolly C, Del RC, Valles B, et al. Phase I trial of maintenance Sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transpl. 2014;20(12):2042–48.</cite> [<a href="https://doi.org/10.1016/j.bbmt.2014.09.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4253683/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25239228/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20YB,%20Li%20S,%20Lane%20AA,%20Connolly%20C,%20Del%20RC,%20Valles%20B,%20et%20al.%20Phase%20I%20trial%20of%20maintenance%20Sorafenib%20after%20allogeneic%20hematopoietic%20stem%20cell%20transplantation%20for%20fms-like%20tyrosine%20kinase%203%20internal%20tandem%20duplication%20acute%20myeloid%20leukemia.%20Biol%20Blood%20Marrow%20Transpl.%202014;20(12):2042%E2%80%9348." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The data that support the findings of this study are available from the corresponding author at 356135708@qq.com upon reasonable request.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Biomarker Research are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s40364-025-00816-9"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/40364_2025_Article_816.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.2 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12366021/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12366021/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12366021%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366021/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12366021/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12366021/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40830801/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12366021/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40830801/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12366021/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12366021/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="DMqZiVz2i2HmqnqK21WzasmVYU0MiTPoBMozZev3Y4zWeSLEDxdA0Sy1B6WfQcwb">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
